Department of Pharmaceutical Sciences, University of Maryland, 20 Penn Street, Baltimore, MD 21201, USA.
Eli Lilly & Co, Indianapolis, IN, USA.
Pharmacol Ther. 2018 Dec;192:88-99. doi: 10.1016/j.pharmthera.2018.06.013. Epub 2018 Jun 30.
Drug transporter proteins are critical to the distribution of a wide range of endogenous compounds and xenobiotics such as hormones, bile acids, peptides, lipids, sugars, and drugs. There are two classes of drug transporters- the solute carrier (SLC) transporters and ATP-binding cassette (ABC) transporters -which predominantly differ in the energy source utilized to transport substrates across a membrane barrier. Despite their hydrophobic nature and residence in the membrane bilayer, drug transporters have dynamic structures and adopt many conformations during the translocation process. Whereas there is significant literature evidence for the substrate specificity and structure-function relationship for clinically relevant drug transporters proteins, there is less of an understanding in the regulatory mechanisms that contribute to the functional expression of these proteins. Post-translational modifications have been shown to modulate drug transporter functional expression via a wide range of molecular mechanisms. These modifications commonly occur through the addition of a functional group (e.g. phosphorylation), a small protein (e.g. ubiquitination), sugar chains (e.g. glycosylation), or lipids (e.g. palmitoylation) on solvent accessible amino acid residues. These covalent additions often occur as a result of a signaling cascade and may be reversible depending on the type of modification and the intended fate of the signaling event. Here, we review the significant role in which post-translational modifications contribute to the dynamic regulation and functional consequences of SLC and ABC drug transporters and highlight recent progress in understanding their roles in transporter structure, function, and regulation.
药物转运蛋白对于广泛的内源性化合物和外源性物质(如激素、胆汁酸、肽、脂质、糖和药物)的分布至关重要。药物转运蛋白有两类——溶质载体(SLC)转运蛋白和 ATP 结合盒(ABC)转运蛋白——它们主要区别在于用于将底物跨膜转运的能量来源。尽管药物转运蛋白具有疏水性和位于膜双层中,但它们具有动态结构,并在转运过程中采用多种构象。尽管有大量文献证据表明临床相关药物转运蛋白的底物特异性和结构-功能关系,但对于导致这些蛋白功能表达的调节机制的了解较少。已经表明,翻译后修饰通过广泛的分子机制来调节药物转运蛋白的功能表达。这些修饰通常通过在溶剂可及的氨基酸残基上添加一个功能基团(例如磷酸化)、一个小蛋白(例如泛素化)、糖链(例如糖基化)或脂质(例如棕榈酰化)来进行。这些共价添加通常是信号级联的结果,并且可能是可逆的,这取决于修饰的类型和信号事件的预期命运。在这里,我们回顾了翻译后修饰对 SLC 和 ABC 药物转运蛋白的动态调节和功能后果的重要作用,并强调了理解它们在转运体结构、功能和调节中的作用的最新进展。